---
created: '2026-02-08T19:45:44.447653Z'
description: A type of fat stored in the body. Elevated levels increase cardiovascular
  disease risk and are associated with metabolic syndrome.
dg-home: false
dg-publish: true
gardenUsername: dev_admin
permalink: /garden/dev_admin/biomarker/triglycerides/
slug: triglycerides
tags:
- biomarker
title: Triglycerides
type: biomarker
updated: '2026-02-08T19:45:44.447653Z'
---

# Triglycerides

## Overview
No description available.

## Reference Ranges
Reference ranges not available.


## Testing Information
- **Measurement Unit**: Not specified
- **Sample Type**: Not specified
- **Fasting Required**: False
- **Recommended Test Frequency**: Not specified



<!-- NEO4J_CONTENT_START -->
## Relationships
### Related
- ‚Üê [[triglycerides]] (labtest)
```yaml
last_modified: '2026-01-26T06:48:28.183752'
source: obsidian
```
- ‚Üê [[lipid_panel_standard]] (labtest)
```yaml
last_modified: '2026-01-26T06:48:19.242090'
source: obsidian
```
- ‚Üê [[advanced_lipid_panel]] (labtest)
```yaml
last_modified: '2026-01-26T06:48:06.527789'
source: obsidian
```
- ‚Üí [[lipid_panel_standard]] (labtest)
```yaml
last_modified: '2026-01-26T06:47:24.411186'
source: obsidian
```
- ‚Üí [[advanced_lipid_panel]] (labtest)
```yaml
last_modified: '2026-01-26T06:47:24.411186'
source: obsidian
```
- ‚Üí [[advanced_lipid_panel]] (entity)
```yaml
last_modified: '2026-01-26T07:07:17.986638'
source: obsidian
```
- ‚Üí [[Metabolic_Syndrome]] (entity)
```yaml
last_modified: '2026-01-26T07:07:17.986638'
source: obsidian
```
- ‚Üí [[lipid_panel_standard]] (entity)
```yaml
last_modified: '2026-01-26T07:07:17.986638'
source: obsidian
```
- ‚Üí [[Insulin_Resistance]] (entity)
```yaml
last_modified: '2026-01-26T07:07:17.986638'
source: obsidian
```
- ‚Üí [[Omega-3_Fatty_Acids]] (entity)
```yaml
last_modified: '2026-01-26T07:07:17.986638'
source: obsidian
```
- ‚Üí [[Cardiovascular_Risk_Pattern]] (entity)
```yaml
last_modified: '2026-01-26T07:07:17.986638'
source: obsidian
```
- ‚Üí [[triglycerides]] (labtest)
```yaml
last_modified: '2026-01-26T07:07:17.986638'
source: obsidian
```
- ‚Üí [[Omega-3_Fatty_Acids]] (supplement)
```yaml
last_modified: '2026-01-26T07:07:17.986638'
source: obsidian
```
- ‚Üê [[Berberine]] (drug)
```yaml
last_modified: '2026-01-26T07:07:40.282261'
source: obsidian
```
- ‚Üê [[Metabolic_Syndrome]] (condition)
```yaml
last_modified: '2026-01-26T07:07:32.678592'
source: obsidian
```
- ‚Üê [[Insulin_Resistance]] (condition)
```yaml
last_modified: '2026-01-26T07:07:30.181114'
source: obsidian
```
- ‚Üê [[Cardiovascular_Risk_Pattern]] (clinicalpattern)
```yaml
last_modified: '2026-01-26T07:07:20.045782'
source: obsidian
```
- ‚Üê [[Omega-3_Fatty_Acids]] (supplement)
```yaml
last_modified: '2026-01-26T07:08:39.989104'
source: obsidian
```
- ‚Üê [[Berberine]] (supplement)
```yaml
last_modified: '2026-01-26T07:08:35.916356'
source: obsidian
```
- ‚Üí [[Berberine]] (drug)
```yaml
last_modified: '2026-01-26T07:07:17.986638'
source: obsidian
```
- ‚Üí [[Triglycerides]] (biomarker)
```yaml
last_modified: '2026-01-26T07:07:17.986638'
source: obsidian
```

### Decreases Biomarker
- ‚Üê [[Omega-3_Fatty_Acids]] (supplement)
```yaml
effect_direction: decreases
evidence_level: 5
last_modified: '2026-01-26T07:08:39.853055'
magnitude: strong
magnitude_range: 25-30% reduction
notes: FDA-approved for hypertriglyceridemia at 4g/day. Dose-response relationship
  well established.
onset_timeframe: 4-12 weeks
population_context: elevated triglycerides
source: obsidian
study_references:
- PMID:30586774
- PMID:31422671
```

### Requires Biomarker
- ‚Üê [[Metabolic_Syndrome]] (condition)
```yaml
last_modified: '2026-01-26T07:07:21.922538'
source: obsidian
```
- ‚Üê [[Insulin_Resistance]] (condition)
```yaml
last_modified: '2026-01-26T07:07:20.706349'
source: obsidian
```
- ‚Üê [[Cardiovascular_Risk_Pattern]] (clinicalpattern)
```yaml
last_modified: '2026-01-26T07:07:20.311340'
source: obsidian
```
<!-- NEO4J_CONTENT_END -->
## Relationships

### Influences
No known influences documented.

### Correlations
No correlations documented.

### Other Relationships
### Related
- ‚Üí [[Omega-3_Fatty_Acids]] (entity)
```yaml
last_modified: '2026-01-19T09:30:28.888881'
source: obsidian
```
- ‚Üí [[Berberine]] (drug)
```yaml
last_modified: '2026-01-19T09:30:28.888881'
source: obsidian
```
- ‚Üí [[Triglycerides]] (biomarker)
```yaml
last_modified: '2026-01-19T09:30:28.888881'
source: obsidian
```
- ‚Üê [[Berberine]] (supplement)
```yaml
last_modified: '2026-01-19T09:06:58.948673'
source: obsidian
```
- ‚Üê [[Omega-3_Fatty_Acids]] (supplement)
```yaml
last_modified: '2026-01-19T09:07:12.965838'
source: obsidian
```
- ‚Üí [[Cardiovascular_Risk_Pattern]] (entity)
```yaml
last_modified: '2026-01-19T09:30:28.888881'
source: obsidian
```
- ‚Üí [[Insulin_Resistance]] (entity)
```yaml
last_modified: '2026-01-19T09:30:28.888881'
source: obsidian
```
- ‚Üí [[Metabolic_Syndrome]] (entity)
```yaml
last_modified: '2026-01-19T09:30:28.888881'
source: obsidian
```
- ‚Üê [[Cardiovascular_Risk_Pattern]] (clinicalpattern)
```yaml
last_modified: '2026-01-19T09:30:37.203726'
source: obsidian
```
- ‚Üê [[Insulin_Resistance]] (condition)
```yaml
last_modified: '2026-01-19T09:31:13.820465'
source: obsidian
```
- ‚Üê [[Metabolic_Syndrome]] (condition)
```yaml
last_modified: '2026-01-19T09:31:23.144461'
source: obsidian
```
- ‚Üê [[Berberine]] (drug)
```yaml
last_modified: '2026-01-19T09:31:50.148655'
source: obsidian
```

### Requires Biomarker
- ‚Üê [[Cardiovascular_Risk_Pattern]] (clinicalpattern)
```yaml
last_modified: '2026-01-19T09:30:36.399745'
source: obsidian
```
- ‚Üê [[Insulin_Resistance]] (condition)
```yaml
last_modified: '2026-01-19T09:30:38.659417'
source: obsidian
```
- ‚Üê [[Metabolic_Syndrome]] (condition)
```yaml
last_modified: '2026-01-19T09:30:42.706915'
source: obsidian
```

### Decreases Biomarker
- ‚Üê [[Omega-3_Fatty_Acids]] (supplement)
```yaml
effect_direction: decreases
evidence_level: 5
last_modified: '2026-01-19T09:07:12.526277'
magnitude: strong
magnitude_range: 25-30% reduction
notes: FDA-approved for hypertriglyceridemia at 4g/day. Dose-response relationship
  well established.
onset_timeframe: 4-12 weeks
population_context: elevated triglycerides
source: obsidian
study_references:
- PMID:30586774
- PMID:31422671
```

## üíä Supplements That Affect This Biomarker

- [[Omega-3 Fatty Acids]] - Decreases triglycerides 25-30% (evidence level 5, FDA-approved)

## üß™ Lab Tests That Measure This Biomarker

### Direct Tests
- [[triglycerides]] - Direct triglyceride measurement

### Panel Tests
- [[lipid panel standard]] - Standard lipid panel
- [[advanced lipid panel]] - Advanced lipid panel

## References
No references available.

## Dataview Queries
```dataview
LIST
FROM [[Triglycerides]]
WHERE contains(type, "Intervention")
SORT confidence_score DESC
```